|
| General Information |
| Business: |
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. We have a powerful pipeline of clinical drug candidates, led by our programs for the treatment of Alzheimer’s disease (“AD”) and type 2 diabetes. Our drug candidate for the treatment of AD, azeliragon (TTP488), is an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (“RAGE”), and we have commenced patient enrollment in a Phase 3 clinical trial (the “STEADFAST Study”) under an FDA-agreed Special Protocol Assessment (“SPA”). Our type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (“GKA”), for which we are currently enrolling patients in a Phase 2b clinical trial (the “AGATA Study”), and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (“GLP-1r”), which we anticipate will enter a Phase 2 clinical trial in early 2016. We have three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
35 |
Founded: |
2015 |
|
| Contact Information |
| Address: |
4170 Mendenhall Oaks Pkwy, High Point, NC 27265, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 1.6 mil (last 12 months) |
|
| Net Income: |
$ -30.8 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
VTVT |
| Shares (millions): |
7.8 |
| Price Range: |
$15.00 - $15.00 |
| Est.$ Volume |
$ 117.2 mil |
| Manager / Joint Managers |
Piper Jaffray/ Stifel |
| Co Managers |
Canaccord Genuity/ Janney Montgomery Scott |
| Expected to Trade |
7/30/2015 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
